IlluminOss Medical, Inc., a privately held medical device company in East Providence, Rhode Island, has named Dwayne Montgomery its Senior Vice President of Sales and Marketing. Montgomery, who has 20 years of experience in orthopedic, spine and cardiac markets, was most recently Vice-President of Commercial Operations at TranS1, Inc. (now Baxano Surgical, Inc.) where he was responsible for North American sales and operations.
Dwayne Montgomery Joins IlluminOss Medical
1 min read Premium comments
Formerly, Montgomery was the Global Vice President and General Manager for Smith & Nephew, Inc’s Orthopedic Trauma Division where he was responsible for global strategic directions, including a $400M sales business. He holds a BS Degree in Chemistry from the University of North Alabama, an MBA from the Jack C. Massey School of Business at Belmont University and strategic marketing certificates from University of Michigan and University of Texas Schools of Business.
“Dwayne has an exceptional track record in orchestrating winning sales strategies for companies in some of the most competitive healthcare markets and has vast commercial experience centered on quickly developing strong surgeon relationships, ” said Dirk Kuyper, president and CEO of IlluminOss. “He is well respected by his colleagues for possessing exceptional business acumen. Dwayne is exactly the addition our team needs to reach our sales goals as we move into the commercial ramp phase of the company.”
IlluminOss maintains CE Mark for clinical applications in light to low load bearing bones and is extending the platform technology to other extremities and applications. The company has direct distribution in Germany and is expanding in Europe with the recent addition of exclusive distribution in several key markets. The IlluminOss products are Investigational Devices; limited by U.S. Federal law to Investigational Use and are not approved for sale in the USA.
Company officials say that the global bone fracture repair market amounted to $5.5 billion in sales in 2010 and is growing at the rate of approximately 6% per annum, driven by population growth and aging populations around the globe.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.